Regulations Favor the Giants
Independent pharmacies operate under a regulatory framework written by and for the largest chain drugstores. The FDA's track-and-trace rules, state-level audit requirements, and pharmacy benefit manager contracts create compliance costs that small operators cannot spread across thousands of store locations. A neighborhood pharmacy with two employees and a single counter faces the same paperwork burden as a CVS with a regional legal team. That is not patient safety. It is market protection.
The National Community Pharmacists Association reports that independent pharmacies fill roughly 1.5 billion prescriptions annually despite declining numbers. Since 2010, more than 2,300 independent pharmacies have closed. Compliance costs, not clinical failures, drive most of those closures. Regulators measure inputs, not outcomes, and patients lose access to local care.
The Drug Supply Chain Security Act of 2013 requires every prescription drug package to be traced from manufacturer to dispenser by November 2024. Smaller pharmacies spent thousands of dollars on scanner hardware and software upgrades to meet the deadline. Large chains absorbed those costs as rounding errors. The result is a compliance moat that protects incumbents from new competitors and makes it harder for independent owners to survive.
State boards of pharmacy add another layer. Many states require separate permits for compounding, durable medical equipment, and medication therapy management. Each permit carries fees, inspections, and continuing education requirements. Independent pharmacists must navigate this maze with limited staff. Chain pharmacies deploy compliance officers who specialize in nothing else.
The track-and-trace mandate also makes independent pharmacies reluctant to stock less common medications. If a package cannot be authenticated through the electronic system, the pharmacist cannot sell it. That means specialty drugs for rare conditions may sit in chain warehouses while patients wait. Small pharmacies that once served niche populations now send those patients elsewhere.
Pharmacy Benefit Managers Skew the Market
Pharmacy benefit managers control which drugs are covered, how much pharmacies are reimbursed, and which pharmacies patients are allowed to use for their prescriptions. Three companies, CVS Caremark, Express Scripts, and OptumRx, handle more than 80% of all prescriptions filled in the United States each year. Their contracts often include clauses that independent pharmacies cannot negotiate, such as direct and indirect remuneration fees that claw back reimbursements months after a sale. The Federal Trade Commission has documented these practices in multiple reports.
The FTC's 2024 interim report on pharmacy benefit managers found that vertical integration between insurers, drugstores, and benefit managers creates conflicts of interest that raise prices. When a PBM owned by CVS steers patients toward CVS pharmacies, independent competitors lose volume. Lost volume means less leverage with wholesalers. Less leverage means higher acquisition costs. The cycle is deliberate.
Some states have tried to fight back. Arkansas passed a law requiring PBMs to reimburse pharmacies at rates no lower than their acquisition costs. The Pharmaceutical Care Management Association challenged it in court, and the case reached the Supreme Court in Rutledge v. PCMA. The Court upheld the state law in 2020, but the ruling left plenty of room for benefit managers to adjust contracts in other ways. The war did not end with one decision.
Patients pay the price. A 2023 Government Accountability Office study found that Medicare Part D enrollees paid more out of pocket when PBMs restricted pharmacy choice. Independent pharmacies often provide lower cash prices and personal counseling, but patients never learn that because their plans steer them elsewhere. Regulatory capture hides competition in plain sight.
Congress has considered PBM reform for years. The Senate Finance Committee advanced bipartisan legislation in 2024, and the House Energy and Commerce Committee held hearings this spring. Yet the final language keeps getting weaker. Lobbyists for the largest pharmacy and insurance groups swarm Capitol Hill whenever a transparency provision gains traction. The result is a parade of hearings and a shortage of votes.
Patients Lose When Competition Dies
Independent pharmacies are not quaint relics of a bygone era, and their disappearance would leave millions of Americans without a local source of care. They are small businesses that provide medication synchronization, vaccine administration, and chronic disease coaching in communities that national chains have abandoned. Rural America depends on them. When one closes, patients drive farther, wait longer, and receive less personalized care.
The data is stark. The Rural Health Research Center at the University of Minnesota found that 604 rural pharmacies closed between 2003 and 2021. Closures accelerated after 2018, precisely when reimbursement pressure and direct and indirect remuneration fees intensified. Each closure represents a town that lost a health care anchor and a pharmacist who knew patients by name.
Technology could help if regulators allowed it. Automated dispensing systems, app-based refill reminders, and remote pharmacist consultations reduce overhead and improve adherence. But state and federal rules often lag behind innovation. A pharmacist who wants to offer telehealth services may need a separate license in each state where a patient lives. That barrier protects no one. It only preserves the status quo.
Reform should start with transparency. PBMs should report actual drug costs, rebate amounts, and pharmacy reimbursements to regulators and plan sponsors. State boards should allow telepharmacy and permit independent operators to compete on service rather than paperwork. The FDA should streamline track-and-trace requirements for small dispensers without weakening safety.
Libertarians and conservatives share an interest in this fight. Both distrust centralized control and crony arrangements that privilege the biggest players. Health care is no exception. A market where independent pharmacists can thrive would lower prices, expand access, and restore the doctor-patient-pharmacist relationship. Washington's current regulatory architecture does the opposite. It deserves a thorough teardown.
